LONDON (ShareCast) - (ShareCast News) - Speciality pharmaceutical company Alliance Pharma said it was trading in line with expectations, with sales of around £22.8m in in the six months ended June 30, up from £21.4m in the same period last year.
In a trading update ahead of its interim results, the company said its growth products continue to deliver, with its Hydromol ointment generating sales of £.3.3m in the period, 10% higher than the same time last year, despite the additional Pharmaceutical Price Regulation Scheme rebate reduction.

The company said its eye care brand, MacuShield, which it acquired in February this year, is performing in line with expectations. It added that it looks forward to the return of ImmuCyst in the second half of the year, although volumes remain uncertain as Sanofi's facility ramps up production.

Alliance said it continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year.

The company's interim results for the six months ended 30 June 2015 are scheduled to be released on 9 September 2015.

At 15:30, shares were down 0.3% at 44.64p

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE